BRCA1 and breast carcinoma: The ESMO clinical practice guidelines [2] for primary breast cancer published in 2015 do not recommend platinum agents for routine use for BRCA1/2 mutation carriers; however, these guidelines state that adding a platinum compound to NACT, after discussion with the patient, is acceptable.